Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov;339(2):687-93.
doi: 10.1124/jpet.111.184663. Epub 2011 Aug 22.

Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice

Affiliations

Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice

Taline V Khroyan et al. J Pharmacol Exp Ther. 2011 Nov.

Abstract

1-(1-Cyclooctylpiperidin-4-yl)-indolin-2-one (SR14150) and 1-(1-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidinl-4-yl)-indolin-2-one (SR16835) are moderately selective nociceptin/orphanin FQ (NOP) receptor agonists. In the [(35)S]guanosine 5'-O-(3-thiotriphosphate) assay in vitro, SR14150 is a partial agonist at both the NOP and μ-opioid receptors, whereas SR16835 is a full agonist at the NOP receptor and has low efficacy at μ receptors. These compounds were tested for antinociceptive and antiallodynic activity, using mice in chronic pain, subsequent to spinal nerve ligation (SNL) surgery. When administered subcutaneously to mice after SNL surgery, SR14150 but not SR16835 increased tail-flick latency, which was blocked by the opioid antagonist naloxone, but not by the NOP receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111). In contrast, both SR14150 and SR16835 had antiallodynic activity when mechanical allodynia was measured with von Frey monofilaments. This effect was completely blocked by SB-612111 but not by naloxone. On the other hand, morphine antinociception and antiallodynia were both blocked by naloxone and potentiated by SB-612111. These results indicate that, in mice, circuitry mediating antinociceptive activity in acute and chronic pain states is different. It is possible that during a chronic pain state, an up-regulated NOP system in the spinal cord leads to NOP receptor-mediated antiallodynia, which is blocked by NOP antagonists. However, supraspinal up-regulation could lead to an attenuation of morphine antinociception and antiallodynia, which can be alleviated by an NOP receptor antagonist. Thus, although neither NOP agonists nor antagonists are effective as analgesics in acute pain, they may have efficacy as analgesics, either alone or in combination with morphine, for treatment of chronic pain.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Chemical structures of SR14150 and SR16835.
Fig. 2.
Fig. 2.
Effect of SR14150 administered alone (A) or coadministered with NOP receptor antagonist SB-612111 or opioid antagonist naloxone (B) on tail-flick latency in mice that have undergone SNL. Morphine is included as the positive control. Data are means ± S.E.M. *, significant difference from vehicle controls; +, significant difference from morphine control; †, significant difference from SR14150 alone (P < 0.05).
Fig. 3.
Fig. 3.
Effect of SR14150 administered alone (A) or coadministered with NOP receptor antagonist SB-612111 or opioid antagonist naloxone (B) on mechanical allodynia induced by SNL. Morphine is included as the positive control. Data are means ± S.E.M. *, significant difference from vehicle controls; †, significant difference from SR14150 alone (P < 0.05).
Fig. 4.
Fig. 4.
Effect of SR16835 administered alone on tail-flick latency in mice that have undergone SNL. Morphine is included as the positive control. Data are means ± S.E.M. *, significant difference from vehicle controls (P < 0.05).
Fig. 5.
Fig. 5.
Effect of SR16835 administered alone (A) or coadministered with NOP receptor antagonist SB-612111 or opioid antagonist naloxone (B) on mechanical allodynia induced by SNL. Morphine is included as the positive control. Data are means ± S.E.M. *, significant difference from vehicle controls; +, significant difference from morphine control; †, significant difference from SR16835 alone (P < 0.05).
Fig. 6.
Fig. 6.
Effect of morphine administered alone or coadministered with NOP receptor antagonist SB-612111 or opioid antagonist naloxone on tail-flick latency in mice that have undergone SNL. Data are means ± S.E.M. *, significant difference from vehicle controls; +, significant difference from morphine alone (P < 0.05).
Fig. 7.
Fig. 7.
Effect of morphine administered alone (A) or coadministered with NOP receptor antagonist SB-612111 or opioid antagonist naloxone (B) on mechanical allodynia induced by SNL. Data are means ± S.E.M. *, significant difference from vehicle controls; +, significant difference from morphine alone (P < 0.05).

Similar articles

Cited by

References

    1. Barlocco D, Cignarella G, Giuseppe G, Grugni M, Ronzoni S. (2006) inventors; GlaxoSmithKline S.p.A., assignee. Benzosuberonylpiperidine compounds as analgesics. U.S. patent 7,115,633 2006 Oct 3
    1. Bertorelli R, Bastia E, Citterio F, Corradini L, Forlani A, Ongini E. (2002) Lack of the nociceptin receptor does not affect acute or chronic nociception in mice. Peptides 23:1589–1596 - PubMed
    1. Bertorelli R, Corradini L, Rafiq K, Tupper J, Calò G, Ongini E. (1999) Nociceptin and the ORL-1 ligand [Phe1ψ (CH2-NH)Gly2]nociceptin(1–13)NH2 exert anti-opioid effects in the Freund's adjuvant-induced arthritic rat model of chronic pain. Br J Pharmacol 128:1252–1258 - PMC - PubMed
    1. Briscini L, Corradini L, Ongini E, Bertorelli R. (2002) Up-regulation of ORL-1 receptors in spinal tissue of allodynic rats after sciatic nerve injury. Eur J Pharmacol 447:59–65 - PubMed
    1. Carrà G, Rizzi A, Guerrini R, Barnes TA, McDonald J, Hebbes CP, Mela F, Kenigs VA, Marzola G, Rizzi D, et al. (2005) [(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor. J Pharmacol Exp Ther 312:1114–1123 - PubMed

Publication types

MeSH terms